This bill extends by 180 days the relevant periods of market exclusivity for drugs for rare diseases or conditions (i.e., orphan drugs) for which applications were submitted during the COVID-19 emergency period.
2
Where do you stand?
Choose your position
3
Tell your reps
Take a position to see your representatives and ways to contact them.
4
More on this bill
Where it stands
Introduced
2Passed House
3Passed Senate
4To President
5Became Law
Looking ahead
No hearings or votes scheduled.
History
2026
Feb 25Introduced in HouseLatest
Feb 25Referred to the House Committee on Energy and Commerce.Introduced